scholarly journals Platelet-to-lymphocyte ratio: a prognostic factor for patients with advanced hepatocellular carcinoma?

Tumor Biology ◽  
2015 ◽  
Vol 36 (7) ◽  
pp. 4935-4936 ◽  
Author(s):  
Xiao-cai Tian ◽  
Fu-ren Zeng ◽  
De-hua Wu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factor ◽  
Advanced Hepatocellular Carcinoma ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio

Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma

Tumor Biology ◽  
2014 ◽  
Vol 36 (4) ◽  
pp. 2263-2269 ◽  
Author(s):  
Xing Li ◽  
Zhan-Hong Chen ◽  
Yan-Fang Xing ◽  
Tian-Tian Wang ◽  
Dong-Hao Wu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factor ◽  
Advanced Hepatocellular Carcinoma ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio

Myeloid-deprived suppressor cell mediated the prognostic value of platelet-to-lymphocyte ratio for advanced hepatocellular carcinoma patients.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 331-331
Author(s):  
Xing Li ◽  
Xiang-yuan Wu ◽  
Nan Jiang ◽  
Yan-Fang Xing ◽  
Dong-hao Wu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Targeted Therapy ◽  
Prognostic Value ◽  
Mononuclear Cells ◽  
Suppressor Cell ◽  
Advanced Hepatocellular Carcinoma ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Platelet Counts ◽  
Healthy Donors

331 Background: Myeloid Deprived Suppressor Cell (MDSC) has been recoganized as a promising target for hepatocellular carcinoma (HCC). However, targeted therapy on MDSC failed to display convincing efficacy. Optimization of patient selection to find the most potential beneficiaries might be a solution to this issue. In the present study, we aimed to identify clinical parameters relevant to MDSC level in HCC patients for future MDSC targeted therapy. Methods: In the present study, a series of 55 HCC patients (prospective group) and 20 healthy donors were analyzed investigating frequencies of MDSC in peripheral blood mononuclear cells (PBMC). Results: As a result, we found that MDSC level was increased in HCC patients compared to healthy donors (10.33% vs 1.54%, p< 0.0001). The monocytes (r2= 0.2875, p< 0.0001), neutrophils (r2= 0.3630, p< 0.0001) and platelet counts (r2= 0.0828, p= 0.0331) in circulation was positively associated with MDSC level. Then, the prognostic value of the above predictors was determined in a retrospective database of 243 HCC patients (retrospective group). The baseline characteristics of prospective and retrospective group were similar. Platelet-to-lymphocyte ratio (PLR) were confirmed to be an independent predictor for OS ( p= 0.003) with the rest parameters presented negative results. Then, advanced HCC patients were divided into two groups based on PLR value ≤111.23 or > 111.23 according to ROC analysis. Patients with low PLR presented higher 3-month survival rate (57.6% vs 37.6%) compared with patients with high PLR. PLR was associated with aggressive behavior of malignancies, such as distant metastasis and portal vein thrombosis. Conclusions: In summary, the present study firstly indentified blood platelet counts was a predictor of MDSC level in PBMC for HCC patients. And, patients with higher PLR might be the optimal patient subgroup for MDSC targeted therapy.

scholarly journals Erratum to: Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma

Tumor Biology ◽  
2016 ◽  
Vol 37 (9) ◽  
pp. 12903-12903
Author(s):  
Xing Li ◽  
Zhan-Hong Chen ◽  
Xiao-Kun Ma ◽  
Jie Chen ◽  
Dong-Hao Wu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factor ◽  
Neutrophil To Lymphocyte Ratio ◽  
Advanced Hepatocellular Carcinoma ◽  
Lymphocyte Ratio

Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma

Tumor Biology ◽  
2014 ◽  
Vol 35 (11) ◽  
pp. 11057-11063 ◽  
Author(s):  
Xing Li ◽  
Zhan-Hong Chen ◽  
Xiao-Kun Ma ◽  
Jie Chen ◽  
Dong-Hao Wu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factor ◽  
Neutrophil To Lymphocyte Ratio ◽  
Advanced Hepatocellular Carcinoma ◽  
Lymphocyte Ratio

scholarly journals Comparison of Platelet to Lymphocyte Ratio between Degrees of the Barcelona Clinic Liver Cancer on Hepatocellular Carcinoma Patients at Haji Adam Malik General Hospital

2019 ◽  
Vol 7 (20) ◽  
pp. 3451-3454 ◽  
Author(s):  
Gontar Alamsyah Siregar ◽  
Dedi Irwansyah
Keyword(s):  
Hepatocellular Carcinoma ◽  
Retrospective Study ◽  
Prognostic Factor ◽  
Liver Cancer ◽  
General Hospital ◽  
Inflammatory Marker ◽  
Barcelona Clinic Liver Cancer ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Common Malignancy

BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth most common malignancy. The Barcelona Clinical Liver Cancer System (BCLC), guides the treatment of patients with HCC. Platelet to lymphocyte ratio (PLR) is an inflammatory marker used as a prognostic factor disease of HCC. An increase in PLR indicates higher host's inflammatory response and is associated with aggressive HCC behaviour, according to BCLC. AIM: This study aims to determine the PLRs between among the degrees of BCLC (The Barcelona Clinic Liver Cancer) in HCC patients at Haji Adam Malik General Hospital in Medan during 2015-2016. METHODS: This retrospective study involved 166 patients with HCC who were then classified by the BCLC guidelines. PLRs among the patient's degrees of BCLC were compared using Kruskal Wallis test. RESULTS: A total of 166 HCC patients, 129 (77.7%) were men and 37 (22.3%) were women. The PLR value ​​has a median value of 17841with the lowest value of 1776 and the highest value of 223684. There were differences in PLR levels with various BCLC stages in patients with HCC at Haji Adam Malik Hospital during 2015-2016 (p = 0.026). CONCLUSION: There were differences in PLR levels with various BCLC stages in patients with HCC at Haji Adam Malik Hospital during 2015-2016.

Sign in / Sign up

Export Citation Format

Share Document